基于生理药代动力学模型优化儿童洛匹那韦/利托那韦与利福平联用剂量
本研究建立成人与儿童洛匹那韦/利托那韦(LPV/RTV)合用利福平的生理药代动力学(PBPK)模型,模拟显示健康成人400/100 mg 每日两次LPV/RTV合用利福平600 mg每日一次使LPV稳态AUC下降79%(观察值75%);在2月龄至8岁儿童中,超增强LPV/RTV(1:1)合用WHO修订剂量利福平15 mg/kg每日一次可使多数儿童LPV谷浓度达标。
要点
- 成人400/100 mg 每日两次LPV/RTV合用利福平600 mg每日一次使LPV稳态AUC下降79%。
- 该方案与利福平10 mg/kg每日一次的模拟谷浓度结果相当。
核心结论
- 超增强LPV/RTV(1:1)合用利福平15 mg/kg每日一次可在模拟的HIV/TB合并感染儿童中达到治疗性LPV谷浓度。
研究设计与样本
- 建立成人与儿童LPV/RTV合用利福平的PBPK模型,纳入CYP3A与P-糖蛋白的抑制和诱导。
- 模型开发与评价数据来自儿童艾滋病临床试验组。
- 对2月龄至8岁儿童进行剂量模拟,模拟超增强LPV/RTV合用利福平10与15 mg/kg口服每日一次的暴露。
主要发现
- LPV、RTV和利福平在成人和≥2周龄儿童中的模拟参数均在观察值两倍范围内。
- 健康成人400/100 mg口服LPV/RTV每日两次合用利福平600 mg口服每日一次,模拟LPV稳态AUC下降79%,观察值为75%。
- 儿童LPV/RTV 230/57.5 mg/m2口服每日两次(未合用利福平)与230/230 mg/m2合用利福平10 mg/kg口服每日一次的模拟与观察浓度曲线相当。
关键数值与推荐
- 目标LPV谷浓度阈值为>1 mg/L。
- 对照方案为利福平10 mg/kg口服每日一次。
临床怎么用
- 儿童HIV/TB合并感染需合用利福平时,可考虑超增强LPV/RTV(1:1)方案并按体重模拟结果选择剂量。
- 利福平采用WHO修订的15 mg/kg每日一次剂量时,需关注LPV谷浓度是否达标。
局限性
- 结论基于PBPK模拟,尚未经临床研究验证。
- 模拟人群为2月龄至8岁、体重3.0–24.9 kg的虚拟儿童。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: Treatment of HIV and tuberculosis co-infection leads to significant mortality in pediatric patients, and treatment can be challenging due to the clinically significant drug-drug interaction (DDI) between lopinavir/ritonavir (LPV/RTV) and rifampin. Doubling LPV/RTV results in insufficient lopinavir trough concentrations in pediatric patients. The objective of this study was to leverage physiologically based pharmacokinetic (PBPK) modeling to optimize the adjusted doses of LPV/RTV in children receiving the WHO-revised doses of rifampin (15 mg/kg daily). DESIGN: Adult and pediatric PBPK models for LPV/RTV with rifampin were developed, including CYP3A and P-glycoprotein inhibition and induction. SETTING (OR DATA SOURCE): Data for LPV/RTV model development and evaluation were available from the pediatric AIDS Clinical Trials Group. PATIENTS: Dosing simulations were next performed to optimize dosing in children (2 months to 8 years of age). INTERVENTION: Exposure following super-boosted LPV/RTV with 10 and 15 mg/kg PO daily rifampin was simulated. MEASUREMENTS AND MAIN RESULTS: Simulated parameters were within twofold observations for LPV, RTV, and rifampin in adults and children ≥2 weeks old. The model predicted that, in healthy adults receiving 400/100 mg oral LPV/RTV twice daily (BID), co-treatment with 600 mg oral rifampin daily decreased the steady-state area under the concentration vs. time curve of LPV by 79%, in line with the observed change of 75%. Simulated and observed concentration profiles were comparable for LPV/RTV (230/57.5 mg/m2 ) PO BID without rifampin and 230/230 mg/m2 LPV/RTV PO BID with 10 mg/kg PO daily rifampin in pediatric patients. Sixteen mg/kg of super-boosted LPV (LPV/RTV 1:1) PO BID with 15 mg/kg PO daily rifampin achieved simulated LPV troughs >1 mg/L in ≥93% of virtual children weighing 3.0-24.9 kg, which was comparable with 10 mg/kg PO daily rifampin. CONCLUSIONS: Super-boosted LPV/RTV with 15 mg/kg rifampin achieves therapeutic LPV troughs in HIV/TB-infected simulated children.
引用
- Salerno SN, Capparelli EV, McIlleron H, et al. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. Pharmacotherapy. 2022. PMID: 35607886. doi:10.1002/phar.2703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。